American Association for Cancer Research
Browse
00085472can132066-sup-tab1.pdf (96.82 kB)

Supplementary Table 1 from Notch3 Pathway Alterations in Ovarian Cancer

Download (96.82 kB)
journal contribution
posted on 2023-03-30, 22:06 authored by Wei Hu, Tao Liu, Cristina Ivan, Yunjie Sun, Jie Huang, Lingegowda S. Mangala, Takahito Miyake, Heather J. Dalton, Sunila Pradeep, Rajesh Rupaimoole, Rebecca A. Previs, Hee Dong Han, Justin Bottsford-Miller, Behrouz Zand, Yu Kang, Chad V. Pecot, Alpa M. Nick, Sherry Y. Wu, Ju-Seog Lee, Vasudha Sehgal, Prahlad Ram, Jinsong Liu, Susan L. Tucker, Gabriel Lopez-Berestein, Keith A. Baggerly, Robert L. Coleman, Anil K. Sood

PDF file - 96K, Notch Pathway Alterations in Patients with HGS-OvCa.

History

ARTICLE ABSTRACT

The Notch pathway plays an important role in the growth of high-grade serous ovarian (HGS-OvCa) and other cancers, but its clinical and biologic mechanisms are not well understood. Here, we found that the Notch pathway alterations are prevalent and significantly related to poor clinical outcome in patients with ovarian cancer. Particularly, Notch3 alterations, including amplification and upregulation, were highly associated with poor patient survival. Targeting Notch3 inhibited ovarian cancer growth and induced apoptosis. Importantly, we found that dynamin-mediated endocytosis was required for selectively activating Jagged-1–mediated Notch3 signaling. Cleaved Notch3 expression was the critical determinant of response to Notch-targeted therapy. Collectively, these data identify previously unknown mechanisms underlying Notch3 signaling and identify new, biomarker-driven approaches for therapy. Cancer Res; 74(12); 3282–93. ©2014 AACR.

Usage metrics

    Cancer Research

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC